Tags : Conditional Approval

Biotech

Merck’s Ervebo [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Receives EC’s Conditional

Shots: The EC has granted conditional marketing authorization to Ervebo for active immunization of individuals aged ≥ 18yrs. to protect against Ebola virus disease (EVD) caused by Zaire Ebola virus The approval allows Merck to initiate the manufacturing of licensed doses in Germany with its anticipated availability in Q3’20. Additionally, Merck has submitted prequalification status […]Read More